PDCD1 and renal cell carcinoma: In the phase III CheckMate 025 trial, a 23% objective response rate was noted in advanced RCC patients treated with the anti-PD-1 nivolumab; in these patients, nivolumab demonstrated efficacy, safety, and tolerability superior to those of everolimus (100).